Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities

Haematologica

Volumn 90, Issue 10, 2005, Pages 1339-1345

  Van Der Straaten, Hanneke M ^a   Van Biezen, Anja ^b   Brand, Ronald ^b   Schattenberg, Anton V M B ^c   Egeler, Roel M ^d   Barge, Renée M ^d   Comelissen, Jan J ^e   Schouten, Harry C ^f   Ossenkoppele, Gert J ^g   Verdonck, Leo F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Medical Statistics   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Allogeneic transplantation; del(5q) 5; del(7q) 7; Myelodysplastic syndrome

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MYELODYSPLASTIC SYNDROME; NETHERLANDS; PATIENT; RECIPIENT; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIBLING; SURVIVAL RATE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 27144517601     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
2. Mrozek K, Heinonen K, de la Chapelle, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
3. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999;94:3707-16.
4. Bloomfield CD, Herzig GP, Caligiuri MA. Introduction: acute leukemia: recent advances. Semin Oncol 1997;24:1-2.
5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
6. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
7. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92:1910-7.
8. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7:1315-23.
9. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7(4):499-508.
10. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res 2000; 24:653-63.
11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
12. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90:2931-8.
13. Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE, et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68:189-94.
14. Haferlach T. More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity? Leukemia 1996; 10 Suppl 3:S5-S9.
15. Berger R, Bernheim A, Ochoa-Noguera ME, Daniel MT, Valensi F, Sigaux F, et al. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet Cytogenet 1987;28:293-9.
16. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 2005;80:681-98.
17. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52.
18. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996;33:127-38.
19. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Rearing M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome or AML-type chemotherapy. Blood 1997;90:2969-77.
20. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110:620-30.
21. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100:1997-2004.
22. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995;16:203-8.
23. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292:895-902.
24. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002;87:52-8.
25. Silverman LR, Demakos EP, Peterson BL, Komblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429-40.
26. van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004;28:785-90.